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Abstract Erythropoietin (EPO) is a hormone that regulates
red blood cell production. Recombinant human EPO
(rHuEPO) and NESP (novel erythropoiesis stimulating
protein) have been produced for therapeutic purposes and
also to improve sports performance. The primary sequences
of rHuEPO and NESP differ by just five amino acids. Due
to the high homology, no antibodies that are able to
discriminate between both molecules have been obtained
until now. The aim of the present work was to design
synthetic peptides corresponding to the sequence that
differs between EPO and NESP (87–90aa), that can then
be used as immunogens to develop specific rabbit poly-
clonal antibodies for selectively detecting EPO and NESP.
Three peptides were synthesized: EPO (81–95), NESP (81–
95), and NESP (86–104), and these were coupled to KLH
and OVA for immunization and screening purposes,
respectively. The sera obtained were tested by ELISA on
synthetic peptide–OVA conjugates and purified by immu-
noaffinity chromatography against the corresponding syn-
thetic peptide. The specific purified antibodies were
characterized by ELISA, SDS-PAGE, and isoelectric
focusing, followed by western blot. Antisera raised against
EPO (81–95) recognized rHuEPO but not NESP. In
contrast, anti-NESP (84–106) sera gave a specific anti-
NESP response only after immunoaffinity purification on a
NESP (86–91) column. An efficient strategy for generating
specific antibodies against EPO and NESP can be achieved
by selecting suitable synthetic peptides. The antibodies
obtained are able to differentiate between rHuEPO and
NESP, and may be particularly useful for screening
purposes in both therapeutic and antidoping contexts.




BSA bovine serum albumin
ELISA enzyme-linked immunosorbent assay
EPO erythropoietin
HPLC high-performance liquid chromatography
HIV human immunodeficiency virus
IAC immunoaffinity chromatography
IEF immunoelectrofocusing
SDS-PAGE sodium dodecyl sulfate–polyacrylamide
gel electrophoresis
KLH keyhole limpet hemocyanin
MALDI-TOF matrix-assisted laser desorption ionization/
time-of-flight
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Introduction
Erythropoietin (EPO) is a hormone mainly produced by the
peritubular cells in the adult human kidney cortex [1] that
regulates red blood cell production [2]. Human EPO is a
glycoprotein approximately 30 kDa in size [3], and about
40% of its total molecular mass corresponds to three N-
linked (Asn24, Asn38, Asn83) and one O-linked (Ser126)
carbohydrate chains attached to the polypeptide backbone.
Recombinant human EPO (rHuEPO), first obtained in 1985
[1], differs from native EPO in its carbohydrate structure
[4]. rHuEPO has been used extensively to treat certain
forms of anemia associated with chronic renal failure, HIV
infection, rheumatoid arthritis, premature birth, and cancer
[5]; and has also become popular among endurance sport
disciplines as a performance-enhancing agent [6, 7]. A
hyperglycosylated analog of EPO, named NESP (novel
erythropoiesis stimulating protein), has been obtained more
recently [8]. This recombinant analog, which is also
produced in hamster ovary cells (CHO), differs from
rHuEPO by five amino acid residues (Ala30Asn, His32Thr,
Pro87Val, Trp88Asn and Pro90Thr). The presence of two
new asparagines amidst the consensus sequence Asn-Xxx-
Ser/Thr makes the additional attachment of two extra N-
linked oligosaccharide chains, each containing up to four
terminal sialic acid residues, possible. These modifications
increase the molecular mass of NESP to approximately
37 kDa and the number of sialic acid residues up to 22
[5, 8]. In NESP, just like other glycoproteins, the increase in
the number of sialic acid residues results in a longer
circulating half-life and a greater biological activity
compared to rHuEPO. Consequently, NESP can be admin-
istered once a week in order to improve the quality of life
for patients [5].
Until now, a large number of monoclonal and polyclonal
anti-human EPO-specific antibodies have been obtained
and used in several techniques in order to detect EPO in
biological samples from chronic kidney disease patients [9],
as well as in a method used for doping control [6]. Also,
anti-EPO antibodies have been used in capillary electro-
phoresis to detect and preconcentrate EPO in order to
improve on current methods of detection [10, 11]. Anti-
bodies that are able to discriminate between EPO and
NESP, however, have not been described thus far.
The aim of this work was to obtain rabbit polyclonal
antibodies that are able to differentiate between EPO and
NESP, in order to increase detection selectivity. For this
purpose, peptides corresponding to the region (81–104)
with the most sequence differences between rHuEPO and
NESP were synthesized and used as immunogens. The
specificity of the corresponding antibodies in recognizing




rHuEPO samples were obtained from Eprex® (Janssen-
Cilag, High Wycombe, UK). Each prefilled syringe
contained 10,000 IU of epoetin alfa, 0.03% Tween 80,
0.5% glycine, and 1 ml of phosphate buffer. rHuEPO from
the European Pharmacopoeia was used for IEF experi-
ments, and each sample vial contained 250 μg of rHuEPO
(an equimolar mixture of epoetin alfa and beta). NESP
(Darbepoetin alfa) was obtained from Aranesp® (Amgen,
Thousand Oaks, CA, USA),and each prefilled syringe
contained 20 μg of NESP.
Peptide synthesis and coupling
Peptides corresponding to the EPO (81–95) sequence, its
homologous NESP (81–95) and NESP (86–104), as well as
the NESP (86–91)-Ahx affinity probe (Table 1) were
prepared in C-terminal carboxamide form by solid-phase
synthesis methods on 0.1 mmol Rink amide-functionalized
polyethyleneglycol–polystyrene. All sequences had an extra
Cys residue at the C-terminus to allow conjugation to either
carrier protein (first three peptides) or IAC resin (Nesp (86–
91)-Ahx). This latter peptide also had an additional spacer
residue of 6-aminohexanoic acid (Ahx) next to the Cys. The
sequences were assembled in an Applied Biosystems 433
instrument running optimized Fmoc/tBu chemistry that
included (i) piperidine–DMF (1:4) deprotection, and (ii)
couplings with 1 mmol (10 eq) each of Fmoc amino acid,
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-
fluorophosphate and 1-N-hydroxybenzotriazole, in the
presence of 2 mmol N,N-diisopropylethylamine in N,N-
dimethylformamide. Final deprotection and cleavage from
the solid support were performed with trifluoroacetic acid/
thioanisole/water/phenol/ethanedithiol (82.5:5:5:5:2.5) for
3.5 h at room temperature. The crude peptides were purified
by reverse-phase preparative HPLC on C18 silica. Homo-
geneous fractions (>95% by analytical HPLC) were pooled
to give materials of satisfactory composition and mass by
amino acid analysis and MALDI–TOF mass spectrometry,
respectively. For immunization and screening purposes, the
three peptides were coupled to either keyhole limpet
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hemocyanin (KLH) or ovalbumin (OVA) using 3-maleimi-
dobenzoic acid N-hydroxysuccinimide ester (MBS) and
glutaraldehyde conjugation chemistries, respectively. The
peptide content of the conjugates was determined by amino
acid analysis.
Immunization schedule
Two New Zealand rabbits were immunized with 200 μg of
each synthetic peptide–KLH conjugate in MPL-TDM
adjuvant (Sigma, St. Louis, MO, USA) every two weeks,
and were boosted monthly after four immunizations.
Animals were bled from the auricular artery, seven days
after each immunization, starting from the third. Serum
samples were stored frozen at −40 °C until used. Animal
protocols were approved by the CEEA (Ethical Comitee of
Animal Experimentation) of the Institution.
Enzyme-linked immunosorbent assays (ELISA)
ELISA assays were performed on 96-well plates (Maxi-
Sorp, Nunc, Roskilde, Denmark). Wells were coated with
50 μl of the different antigens (peptide–ovalbumin conju-
gate, rHuEPO or NESP) at 10–40 μg/ml in PBS and
incubated at 37 °C for 1 h. Unbound sites were blocked
with PBS–1% gelatin for 30 min. Fifty microliters of total
antisera or purified specific antibodies, diluted in PBS–
0.1% Tween 20 (PBS-T), were added and incubated for 1 h
at 37 °C. After washing, 50 μl of alkaline phosphatase–swine
anti-rabbit immunoglobulins (Dako, Glostrup, Denmark)
diluted 1/1000 were added for 1 h at 37 °C. Reactions were
developed with 50 μl of 4-methylumbelliferyl-phosphate
(Sigma) at 1 mg/ml in triethanolamine buffer (pH 9.5) for
30 min at room temperature, and fluorescence was measured
by excitation at 360 nm and emission at 460 nm in a
Cytofluor™ 2350 (Millipore, Billerica, MA, USA). Pre-
immune rabbit sera were used as the negative control. In
some experiments, rHuEPO and NESP were reduced and
alkylated before coating. For reduction, samples were diluted
in PBS containing 10 mM DTT and incubated at 56 °C for
30 min, and then alkylated with 50 mM iodoacetamide for
30 min at room temperature in the dark. Finally, alkylated
glycoproteins were desalted with Ultrafree-MC 10 kDa
(Millipore).
Immunoaffinity chromatography (IAC)
Antipeptide antibodies were purified by IAC against the
corresponding peptides. The synthetic peptides were cou-
pled to EAH Sepharose 4B (Amersham Biosciences,
Piscataway, NJ, USA) at 1 mg/ml using MBS as a
bifunctional crosslinking agent.
Antipeptide antisera, diluted 1/3 in 10 mM Tris-HCl pH
7.6, were passed through the column 4–5 times (post-
column antiserum). After washing with 10 mM Tris–HCl
and 0.5 M NaCl pH 7.6 to eliminate the nonspecifically
retained fraction (washing fraction), bound antibodies were
eluted with 100 mM glycine–HCl pH 2.5 (elution frac-
tions). Eluted fractions were immediately neutralized with
1 M Tris and kept frozen at −20 °C until use.
SDS–PAGE and western blot
rHuEPO and NESP were applied to 10% SDS–PAGE running
gels and transferred onto nitrocellulose membranes (Protran,
Schleicher and Schuell, Dassel, Germany). In some cases, the
immobilized glycoproteins were partially deglycosylated by
incubating the membrane with 10 mM NaIO4 in 25 mM
sodium acetate buffer pH 4.5 for 1 h at room temperature in
the dark. Non-specific binding sites were blocked using
PBST–1% BSA. Immunoblotting was performed by incu-
bating anti-EPO (81–95) and anti-NESP (86–104) antibodies
for 90 min (diluted 1/20–1/100). After washing with PBS-T,
anti-rabbit-biotin (Dako) diluted 1/3000 was added for 1 h,
and after washing, streptavidin–horseradish peroxidase
(HRP) (Zymed, San Francisco, CA, USA) diluted 1/3000
for 45 min. Finally, reactions were developed using ECL
reagent (Amersham). Pre-immune rabbit sera and a com-
mercial polyclonal anti-EPO antibody (Sigma, ref. E0271)
were used as negative and positive controls, respectively.
Table 1 Sequence, chemical data and conjugation ratios of the synthesized peptides used for the production and purification of antibodies against
rHuEPO and NESP
Name Amino acid sequence HPLC (tR, min) MALDI–TOF MS
b Conjugation ratio
KLH OVA
EPO (81–95) LVNSSQPWEPLQLHVC-NH2 6.0 1849.1 (1848.94) 1044.2 11.3
NESP (81–95) LVNSSQVNETLQLHVC-NH2 4.8 1782 (1782.91) 1916.2 6.2
NESP (86–104) QVNETLQLHVDKAVSGLRSC-NH2 4.8 2196.3 (2196.15) 1367.3 7.0
NESP(86–91)-Ahx QVNETL-Ahx-C-NH2 2.9 702.2 (702.37) – –
aLuna C18 (Phenomenex, Torrance, CA, USA) column, 3 μm particle size, 50×4.6 mm; elution with linear 5–95% gradient of solvent A into B
over 15 min; solvent A: 0.045% (v/v) trifluoroacetic acid in water; solvent B: 0.036% (v/v) trifluoroacetic acid in acetonitrile
bm/z observed; in parentheses, calculated MH+ value
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Immunoelectrofocusing (IEF)
IEF was performed as described previously by Lasne et al.
[6, 12]. In brief, rHuEPO and NESP were applied on a
polyacrylamide gel (T=5%, C=3%, 7 M urea) with a pH
range of 2–6. The samples were focused at a constant
power of 1 W/cm of the gel length until 3600 Vh at 8 °C
using a flat system (Multiphor II Electrophoresis system,
Amersham-Pharmacia). After the IEF, the proteins were
transferred (0.8 mA/cm2, 30 min) to a polyvinylidene
difluoride membrane (PVDF) using a basic transfer buffer
(25 mM Tris–192 mM glycine). The membranes were
incubated with the antibody directly or after pretreatment
with 10 mM NaIO4 in 25 mM sodium acetate buffer, pH
4.5, in order to produce partial deglycosylation.
The purified anti-EPO (81–95) and anti-NESP (86–104)
antibodies were diluted (1/35) with PBS-T and incubated
overnight at room temperature. The polyclonal anti-EPO
antibody from Sigma (ref. E0271) was used at 1/500
dilution with PBS–skim milk (1%) and incubated for 1 h.
The monoclonal anti-human EPO antibody (clone
9C21D11, R&D Systems) was evaluated at different
dilutions (1/1000, 1/500, 1/400, 1/200 and 1/100) and
incubated for 1 h in all cases, and the monoclonal anti-
human EPO antibody (clone AE7A5, R&D Systems,
Minneapolis, MN, USA), which is used as primary
antibody in the IEF method for detecting urinary EPO
during routine doping control, was used as a positive
control under conditions that are described elsewhere [6].
After washing, only the membranes incubated with
commercial antibodies (Sigma) were subjected to the
double blotting procedure [12]. The antibodies were blotted
(0.8 mA/cm2, 30 min) to a second PVDF membrane using
an acidic transfer buffer (0.7% acetic acid). In accordance
with the origin of the primary antibody, anti-rabbit–biotin
(1/3000) or anti-mouse–biotin (1/4000) were used for 1 h at
room temperature. Finally, the membrane was incubated
with streptavidin–HRP (Biospa, SPA, Milano, Italy) for 1 h.
The chemiluminiscent light was produced by the
addition of the peroxidase substrate (SuperSignal West
Femto stable peroxide, Pierce, Rockford, IL, USA). The
light was detected using a CCD camera (luminescent image
analyzer LAS-1000, Fujifilm, Tokyo, Japan).
Results
Peptide selection
Peptides from the region containing three of the five amino
acids that differ between EPO and NESP were selected as
antigens in an attempt to raise antibodies that are able to
differentiate these two glycoproteins. Their amino acid
sequences, chemical data, and the conjugation rates with
KLH and OVA are shown in Table 1. First, two 15-residue
peptides containing the EPO- (81–95) and NESP- (81–95)
specific sequences were synthesized. A cysteine residue
was added to the C-terminal part of each peptide to allow
conjugation to KLH and OVA.
Animals immunized with NESP (81–95)–KLH conju-
gate (n=2) did not develop antibody response to the
peptide. Hence, a second NESP peptide was designed and
synthesized (NESP (86–104)). As shown in Table 1, this
peptide was longer than NESP (81–95) and it had three
differing amino acids in the C-terminal region, which
should make specific immunological recognition more
likely.
Antisera titration and purification by immunoaffinity
chromatography
In order to analyze the levels of the antipeptide antibodies,
pre- and post-immunization anti-EPO (81–95) and anti-
NESP (86–104) sera were tested by ELISA using immobi-
lized peptide–OVA conjugates at 10 μg/ml. No differences
in the antibody titer and the specificity were obtained






















































Fig. 1a, b Titration of the antisera against the peptides used for
immunization. a EPO (81–95) antiserum; b NESP (86–104) antise-
rum. Circles, response to EPO (81–95) peptide; squares, response to
NESP (81–95) peptide; triangles, response to NESP (86–104) peptide.
ELISA well plates were coated with a 10 μg/ml peptide–OVA
conjugate solution
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conjugate. As shown in Fig. 1a, EPO (81–95) antisera
strongly reacted with the EPO (81–95) peptide, showed a
weaker reactivity for the NESP (86–104) peptide, and did
not recognize the NESP (81–95) peptide. In contrast, anti-
NESP (86–104) sera recognized the NESP (86–104)
peptide, recognized the NESP (81–95) peptide to a lower
extent, and did not recognize the EPO (81–95) peptide
(Fig. 1b).
The specific anti-peptide antibodies from EPO (81–95)
and NESP (86–104) antisera were purified by immunoaf-
finity chromatography where the corresponding synthetic
peptide was immobilized to EAH Sepharose 4B. The
different purification fractions were tested by ELISA using
the peptide–OVA conjugates, as described. The flow-
through (post-column) and washing fractions did not react
with the corresponding peptides (data not shown), confirm-
ing that all of the antipeptide antibodies were retained by
the peptide–EAH Sepharose 4B columns. Furthermore, all
of the antipeptide antibodies were found in the first six
elution fractions (data not shown). These results demon-
strated that immobilized EPO (81–95) and NESP (86–104)
peptides efficiently retained all of the anti-EPO (81–95) and
anti-NESP (86–104) antibodies from whole antiserum.
rHuEPO and NESP recognition by ELISA
The capacity of the purified antipeptide antibodies to
recognize entire rHuEPO and NESP were first tested by
ELISA assays. The native rHuEPO and NESP glycopro-
teins and the reduced and alkylated forms were immobi-
lized on 96-well plates. The results, shown in Fig. 2a and b,
indicate that antibodies raised against EPO (81–95) are
able to recognize rHuEPO in its native state. Reduction and
alkylation enhanced their ability to detect rHuEPO, indi-
cating better exposure of the recognized epitopes after
denaturation. In addition, anti-EPO (81–95) antibodies did
not react with either the native NESP or with the reduced
and alkylated form (Fig. 2a). These results suggest a high
specificity of the anti-EPO (81–95) antibodies for the
region of the primary EPO sequence containing the three
amino acids (87–88, 90), which differs between EPO and
NESP. In contrast, anti-NESP (86–104) antibodies recog-
nized both NESP and rHuEPO, although rHuEPO was
recognized to a lesser degree (Fig. 2b). After reduction and
alkylation, the reactivity of the antibodies did not improve.
rHuEPO and NESP recognition by SDS–PAGE
and western blot
The specificities of the purified antibodies were also
assessed by SDS–PAGE/western blot using rHuEPO and
NESP. Figure 3, panels 3 and 4, show that anti-EPO (81–
95) antibodies only recognized rHuEPO (and not NESP),
whereas anti-NESP (86–104) antibodies detected rHuEPO
and NESP, which confirmed the results obtained by ELISA.
The commercial polyclonal anti-EPO antibody (Sigma) also
Fig. 2a, b Antipeptide antibody
recognition of rHuEPO and
NESP in their native state (solid
columns) and reduced-alkylated
state (hatched columns).
rHuEPO columns are indicated
in gray and NESP columns in
black. ELISA test: well plates
were coated with 10 μg/ml of
rHuEPO and NESP and the
antipeptide antibodies were di-
luted 1/20. a) EPO (81–95)
antibody recognition; b) NESP
(86–104) antibody recognition
Fig. 3 Recognition of rHuEPO and NESP by different antibodies after
separation by SDS–PAGE and western blot detection. 1, Molecular
weight standards; 2, commercial polyclonal anti-EPO (Sigma) at 1 μg/ml;
3, EPO (81–95) antibody diluted 1/100; 4, NESP (86–104) antibody
diluted 1/100. Wells contained 0.5 μg of rHuEPO or NESP
Anal Bioanal Chem (2007) 388:1531–1538 1535
recognized both rHuEPO and NESP glycoproteins (Fig. 3,
panel 2).
The limits of detection for rHuEPO and NESP were
determined using decreasing amounts of rHuEPO and NESP.
In order to maximize the sensitivity of the antibodies,
membrane-immobilized proteins were also partially deglyco-
sylated using sodium periodate. As can be seen in Fig. 4, this
treatment enhanced the detection, suggesting that the partial
elimination of the carbohydrate chains improved the recog-
nition of these glycoproteins by the corresponding antipep-
tide antibodies. Moreover, images obtained for low amounts
of protein (62.5 and 31.2 ng) confirmed that anti-NESP (86–
104) antibodies had higher specificity for NESP (Fig. 4b).
At 1/20 antibody dilution, it was possible to detect down to
7 ng of NESP (0.28 μg/ml of NESP) with the anti-NESP
(86–104) antibody and down to 15 ng of rHuEPO (0.6 μg/ml
of rHuEPO) with the antibody against the EPO (81–95)
peptide using reduced and partially deglycosylated glyco-
proteins (data not shown).
NESP (86–91)-Ahx IAC purification
In order to isolate the specific population of antibodies to
NESP contained in the previously purified anti-NESP (86–
104) antibodies, the samples were passed through a column
of immobilized NESP (86–91)-Ahx peptide (QVNETL
region). The results shown in Fig. 5a indicate that most of
the anti-NESP (86–104) antibodies were not retained by the
NESP (86–91)-Ahx column, with the exception of a small
fraction of the antibodies which eluted from fraction 3 to 6,
which specifically recognized the QVNETL sequence. The
specificity of these antibodies to rHuEPO and NESP was
evaluated by ELISA (data not shown) and SDS–PAGE/
western blot. Results shown in Fig. 5b indicate that the
anti-NESP (86–104) antibodies were able to recognize both
rHuEPO and NESP, whereas the NESP (86–91)-Ahx-
purified antibodies selectively detected NESP. Moreover,
this recognition of NESP was improved after partial
deglycosylation using sodium periodate. Although the
signal obtained for the blots with the NESP (86–91)-Ahx-
purified antibodies was rather faint, the results suggest that
the immunization with NESP (86–104)-KLH was able to
induce a specific immune response against the QVNETL-
specific sequence of NESP.
rHuEPO and NESP recognition by IEF
The specificities of the anti-EPO (81–95) and anti-NESP
(86–104) polyclonal antibodies were also evaluated by IEF.
Results indicate that antibodies to EPO (81–95) peptide
kept their specificity for rHuEPO, while NESP was not
detected (Fig. 6, panel 1). Interestingly, the antibodies to


























































Fig. 5a, b Purification and characterization of NESP (86–104) anti-
bodies purified by immunoaffinity chromatography using the synthetic
peptide NESP (86–91)-Ahx. a NESP (86–91)-Ahx column behavior
during purification of the NESP (86–104) antiserum. ELISA test: well
plates were coated with a 10 μg/ml NESP (86–104)–OVA conjugate
solution and each purification fraction diluted 1/240. b SDS–PAGE/
western blot of rHuEPO and NESP with NESP (86–104) antibodies
purified with (1) NESP (86–104) column at 1/100 dilution and
(2) NESP (86–91)-Ahx column at 1/60 dilution. Wells contained 250 ng
of rHuEPO and NESP
Fig. 4a, b Limits of detection for rHuEPO and NESP reached by
SDS–PAGE and western blot using the obtained antipeptide anti-
bodies and different treatments. EPO (81–95) antibody (a) and NESP
(86–104) antibody (b) to reduced proteins (1) and reduced and
partially deglycosylated proteins (2). Antipeptide antibodies were
diluted 1/100
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showed a much higher sensitivity for NESP than for
rHuEPO (Fig. 6, panel 2). The antibodies had the same
specificity, but the sensitivity was enhanced when the
glycoproteins were partially deglycosylated with sodium
periodate, corroborating the SDS–PAGE/western blot
results (Fig. 6, panel 4).
The behavior of the obtained polyclonal antibodies was
compared with commercially available antibodies. Both the
anti-human EPO rabbit polyclonal antibody used as control
in the SDS–PAGE/western blot experiments (Fig. 6, panel 3)
and the monoclonal antibodies (clone AE7A5 and 9C21D11
from R&D) recognized both rHuEPO and NESP under the
IEF conditions; however, they differ in sensitivity. Mono-
clonal anti-human EPO (clone AE7A5) had limits of
detection of better than 0.3 ng for rHuEPO or 0.1 ng for
NESP at 1/1000 dilution (Fig. 6, panel 5), whereas the
monoclonal anti-human EPO 9C21D11 showed much
lower sensitivity but one that was greater for rHuEPO than
for NESP at 1/500 dilution (Fig. 6, panel 4). Under
optimum conditions, including partial deglycosylation over
the membrane, the limit of detection was 5 ng for rHuEPO
and 20 ng for NESP (data not shown).
Discussion
Synthetic peptides corresponding to the N- and C-terminal
sequences of EPO and NESP have been selected in several
instances as immunogens. As the sequences of both
glycoproteins in these regions are identical, antibodies that
are currently available do not discriminate between EPO
and NESP [6, 13–19].
In this work, we designed synthetic peptides of 15–19
amino acids which contain three of the amino acids that
differ in EPO and NESP, in order to develop specific anti-
EPO and anti-NESP antibodies. In the case of the NESP
(81–95) peptide, no specific immune response was
obtained, probably due to the conformation acquired during
the process of conjugation to KLH and the lower
immunogenicity of the VNET (87–90) sequence compared
with the specific EPO (81–95) peptide sequence PWEP. As
previously reported, peptide immunogenicity is determined
by factors such as coupling method, sequence length,
hydrophilicity, accessibility, mobility, and protrusion [20].
In order to obtain anti-NESP specific polyclonal antibodies,
we designed a new synthetic peptide—NESP (86–104)—
containing the specific NESP sequence VNET in the C-
terminal region, which could potentially be more accessible
to the B-cells. The antisera obtained recognize the NESP
and rHuEPO glycoproteins, suggesting that the polyclonal
sera contained a pool of specific antibodies that could
potentially recognize several epitopes present in the peptide
sequence. We isolated the antibodies that specifically
recognized the VNET sequence of NESP using IAC with
immobilized NESP (86–91)-Ahx peptide, which allowed us
to obtain QVNETL-specific antibodies. These antibodies
are able to recognize NESP in ELISA and western blot
assays and they ignore the rHuEPO glycoprotein, indicating
that our immunization–purification strategy is useful for
obtaining polyclonal antibodies against the VNET sequence
of NESP.
The recognition of rHuEPO and NESP by these
antipeptide antibodies was improved by partial deglycosy-
lation as well as reduction and alkylation. Results indicate
that the epitopes recognized by the specific antibodies can
be masked by the carbohydrate chains in the native and
recombinant glycoproteins, and that the folding of the
protein via two disulfide bonds can mask the sequences
where the antibodies bind, as has been described for EPO
[15] and other highly glycosylated proteins that can form
oligomers, such as mucins [21, 22] and CD44 [23].
Polyclonal anti-EPO (81–95) and anti-NESP (86–104)
antibodies were also tested on rHuEPO and NESP by IEF,
which is the method currently used in doping control [6,
Fig. 6 Comparison of the ana-
lysis of rHuEPO and NESP by
IEF using different primary
antibodies and conditions. 1,
EPO (81–95) antibody at 1/35
dilution; 2, NESP (86–104)
antibody at 1/35 dilution; both
antibodies were evaluated under
partial deglycosylation treat-
ment. 3, polyclonal anti-EPO
antibody from Sigma (E0271) at
1/500 dilution; 4, monoclonal
anti-EPO antibody from R&D
(9C21D11) at 1/500 dilution
under partial deglycosylation
treatment; 5, monoclonal anti-
EPO antibody from R&D
(AE7A5) at 1/1000 dilution
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10]. The IEF results agree with those obtained by ELISA
and SDS–PAGE/western blot, confirming the specificity of
the antibodies and also that the sensitivity is enhanced
when the glycoproteins are partially deglycosylated. In
comparison with commercially available antibodies, the
polyclonal antibodies obtained in our study are sufficiently
selective to differentiate EPO and NESP. Although their
sensitivity is still low, and further studies are needed in
order to analyze their reactivity when biological samples
are used, this advantage should prove useful in fields such
as doping or pharmaceutical control.
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